Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Personalis embodies $115m IPO
Personalis has filed to list on the Nasdaq Global Market through an offering that would come eight years after the genome sequencing platform was spun out of Stanford University.
Bicycle Therapeutics squares $60.7m IPO circle
Cambridge Innovation Capital has celebrated an exit as Bicycle Therapeutics successfully lists in the US.
NextCure executes $75m in initial public offering
The immunotherapy developer, which is exploits Yale University research and counts Eli Lilly, Pfizer, Taiho and Ping An as investors, floated in the middle of its range after raising $160m in venture funding.
OssDsign prepares public listing
Regenerative implant producer OssDsign, based on research at Karolinska University Hospital and Uppsala University, hopes to list on the Nasdaq First North and raise $15.8m.
Codiak loads up IPO filing
Exosome therapeutics developer Codiak BioSciences, exploiting technology developed by researchers at the universities of Gothenburg and Texas, is eyeing up to $86.3m in an IPO.
Bicycle Therapeutics to go for a spin on Nasdaq
Cambridge Innovation Capital is in line for an exit as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.
Willow Biosciences follows public path
Willow Biosciences is the result of a three-way merger between University of Calgary spinout Epimeron, BioCan Technologies and CSE-listed Makena Resources.
Precision Bio pinpoints $100m IPO target
Genomic medicine developer Precision Biosciences plans to raise up to $100m in an upcoming IPO that could hand exits to Duke University and corporates Amgen, EMS and Baxter.

Other News

Centogene scents IPO
Rare disease diagnosis technology developer Centogene is gearing up for an IPO having spun out from Rostock in 2006 and raised $28.5m of equity funding in 2017.
Marinomed hits Vienna Stock Exchange
VetMedUni biopharmaceutical spinout Marinomed Biotech has completed its IPO to attain a market cap of $109m.
Venturing in 2018 – the trends
Rob Lavine, News editor for Global Corporate Venturing, reviews the trends in venturing from 2018
Moderna loads up $604m in IPO
Investors including co-founder and Harvard professor Timothy Springer scored exits as mRNA therapy developer Moderna floated in the largest biotech IPO of all time.
Synthorx to synthesise $100m IPO
Synthorx, spun out of Scripps Research Institute, is targeting $100m in a proposed offering half a year after it raised $63m in a series C round backed by Osage University Partners.
Marinomed makes its way to stock exchange
The biopharmaceutical spinout of University of Veterinary Medicine Vienna is issuing 400,000 shares in an initial public offering that is set to fetch between $34m and $41m.

Editor's Picks

Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg